Semaglutide Reduced Heavy Alcohol Drinking by 13.7 Percentage Points vs Placebo in 26-Week Trial of Adults With AUD and Obesity
TL;DR: A 2026 randomized double-blind placebo-controlled trial in The Lancet (N=108 adults with both moderate-to-severe alcohol use disorder and obesity) found that 26 weeks of once-weekly 2.4 mg semaglutide reduced heavy drinking days by 41.1 percentage point…
Read article